QIAGEN (QGEN)
(Delayed Data from NYSE)
$41.65 USD
+0.57 (1.39%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $41.61 -0.04 (-0.10%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QGEN 41.65 +0.57(1.39%)
Will QGEN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for QGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QGEN
Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics
QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches
QGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access
QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
Other News for QGEN
Qiagen Q1 2024 Earnings Preview
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
Bank of America Securities Reaffirms Their Buy Rating on Qiagen (QGEN)
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Deutsche Bank Remains a Buy on Qiagen (QGEN)